A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2015
At a glance
- Drugs Dasatinib (Primary) ; Nilutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacogenomic; Therapeutic Use
- 28 Oct 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Mar 2012 Planned End Date changed from 1 May 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
- 07 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.